Advancing Prevention of Pulmonary Fibrosis

Summary

This study plans to learn more about pulmonary fibrosis and how it develops. We want to determine if the disease can be detected early, before the lung is permanently scarred.

This study will enroll participants who are not currently diagnosed with pulmonary fibrosis, but who have family members with pulmonary fibrosis. Because there is an increased risk within affected families, this cohort will allow us to learn how pulmonary fibrosis develops, and how the lungs change over time.

Conditions

• IPF
• Pulmonary Fibrosis
• ILD

Interventions

OTHER

Sample collection

Blood, Urine, Nail, Hair, Saliva, optional Stool

OTHER

Questionnaires

SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire

RADIATION

High resolution CT scan of the chest

Upon enrollment, all participants will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.

DIAGNOSTIC_TEST

Pulmonary Function Test

All recruited participants will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.

Sponsors & Collaborators

• Mayo Clinic

  collaborator OTHER

• University of California, Los Angeles

  collaborator OTHER

• University of Texas

  collaborator OTHER

• University of Pennsylvania

  collaborator OTHER

• University of Colorado, Denver

  lead OTHER

Principal Investigators

• David Schwartz, MD · University of Colorado School of Medicine

Eligibility

Min Age

40 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-01-22

Primary Completion

2026-08-01

Completion

2026-08-01

Countries

• United States

Study Locations